Steve Finkbeiner, MD, PhD
Director and Senior Investigator, Center for Systems and Therapeutics

Other Professional Titles

Director, Taube/Koret Center for Neurodegenerative Disease Research at Gladstone;
Investigator, Roddenberry Stem Cell Center;
Professor, Neurology and Physiology, University of California, San Francisco

Phone

(415) 734-2508

Fax

(415) 355-0824

Assistant

Kelley Nelson
(415) 734-2509
Barmada SJ, Ju S, Arjun A, Batarse A, Archbold HC, Peisach D, Li X, Zhang Y, Tank EMH, Qiu H et al..  2015.  Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1.. Proc Natl Acad Sci U S A. 112(25):7821-6.
Finkbeiner S, Frumkin M, Kassner PD.  2015.  Cell-based screening: extracting meaning from complex data.. Neuron. 86(1):160-74.
Campioni MR, Finkbeiner S.  2015.  Going retro: ancient viral origins of cognition.. Neuron. 86(2):346-8.
Mason AR, Ziemann A, Finkbeiner S.  2014.  Targeting the low-hanging fruit of neurodegeneration.. Neurology. 83(16):1470-3.
Sieber B-A, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR, Dunlop J, Finkbeiner S, Sutherland M, Wang H et al..  2014.  Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference.. Ann Neurol. 76(4):469-72.
Ochaba J, Lukacsovich T, Csikos G, Zheng S, Margulis J, Salazar L, Mao K, Lau AL, Yeung SY, Humbert S et al..  2014.  Potential function for the Huntingtin protein as a scaffold for selective autophagy.. Proc Natl Acad Sci U S A. 111(47):16889-94.
Qiu H, Lee S, Shang Y, Wang W-Y, Au KFai, Kamiya S, Barmada SJ, Finkbeiner S, Lui H, Carlton CE et al..  2014.  ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects.. J Clin Invest. 124(3):981-99.
S You C, Geschwind MD, Sha SJ, Apple A, Satris G, Wood KA, Johnson ET, Gooblar J, Feuerstein JS, Finkbeiner S et al..  2014.  Executive functions in premanifest Huntington's disease.. Mov Disord. 29(3):405-9.
Kim H-J, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM-Y, Finkbeiner S, Gitler AD, Bonini NM.  2014.  Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models.. Nat Genet. 46(2):152-60.
Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, D Ando M, Tsvetkov A, Pleiss M, Li X, Peisach D et al..  2014.  Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models.. Nat Chem Biol. 10(8):677-85.
Tóth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet J-C, Galvagnion C, Skibinski G et al..  2014.  Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.. PLoS One. 9(2):e87133.
Vieira FG, Ladow E, Moreno A, Kidd JD, Levine B, Thompson K, Gill A, Finkbeiner S, Perrin S.  2014.  Dexpramipexole is ineffective in two models of ALS related neurodegeneration.. PLoS One. 9(12):e91608.
Margulis J, Finkbeiner S.  2014.  Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease.. Front Cell Neurosci. 8:218.
Zhang C, Lopez MS, Dar AC, Ladow E, Finkbeiner S, Yun C-H, Eck MJ, Shokat KM.  2013.  Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.. ACS Chem Biol. 8(9):1931-8.
Kaye JA, Finkbeiner S.  2013.  Modeling Huntington's disease with induced pluripotent stem cells.. Mol Cell Neurosci. 56:50-64.
Tsvetkov AS, Arrasate M, Barmada S, D Ando M, Sharma P, Shaby BA, Finkbeiner S.  2013.  Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration.. Nat Chem Biol. 9(9):586-92.
Aron R, Tsvetkov A, Finkbeiner S.  2013.  NUB1 snubs huntingtin toxicity.. Nat Neurosci. 16(5):523-5.
Serio A, Bilican B, Barmada SJ, Ando DMichael, Zhao C, Siller R, Burr K, Haghi G, Story D, Nishimura ALumi et al..  2013.  Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy.. Proc Natl Acad Sci U S A. 110(12):4697-702.
Bilican B, Serio A, Barmada SJ, Nishimura ALumi, Sullivan GJ, Carrasco M, Phatnani HP, Puddifoot CA, Story D, Fletcher J et al..  2013.  Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells".. Sci Transl Med. 5(188):188le2.
Korb E, Wilkinson CL, Delgado RN, Lovero KL, Finkbeiner S.  2013.  Arc in the nucleus regulates PML-dependent GluA1 transcription and homeostatic plasticity.. Nat Neurosci. 16(7):874-83.
Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A et al..  2013.  Targeting H3K4 trimethylation in Huntington disease.. Proc Natl Acad Sci U S A. 110(32):E3027-36.
Finkbeiner S.  2013.  Startups on the menu.. Nat Biotechnol. 31(8):680.
Sun Y, Dong Z, Jin T, Ang K-H, Huang M, Haston KM, Peng J, Zhong TP, Finkbeiner S, Weiss WA et al..  2013.  Imaging-based chemical screening reveals activity-dependent neural differentiation of pluripotent stem cells.. Elife. 2:e00508.
Tsvetkov AS, D Ando M, Finkbeiner S.  2013.  Longitudinal imaging and analysis of neurons expressing polyglutamine-expanded proteins.. Methods Mol Biol. 1017:1-20.
Korb E, Finkbeiner S.  2013.  PML in the Brain: From Development to Degeneration.. Front Oncol. 3:242.
Arrasate M, Finkbeiner S.  2012.  Protein aggregates in Huntington's disease.. Exp Neurol. 238(1):1-11.
Nucifora LG, Burke KA, Feng X, Arbez N, Zhu S, Miller J, Yang G, Ratovitski T, Delannoy M, Muchowski PJ et al..  2012.  Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein.. J Biol Chem. 287(19):16017-28.
Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, Diaz Z, Fang X, Shorter J, Krogan NJ, Finkbeiner S et al..  2012.  Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.. Nat Genet. 44(12):1302-9.
Sontag EMitchell, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, Necula M, Lau A, Finkbeiner S, Glabe C et al..  2012.  Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.. J Neurosci. 32(32):11109-19.
Peters-Libeu C, Miller J, Rutenber E, Newhouse Y, Krishnan P, Cheung K, Hatters D, Brooks E, Widjaja K, Tran T et al..  2012.  Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure.. J Mol Biol. 421(4-5):587-600.
Bilican B, Serio A, Barmada SJ, Nishimura ALumi, Sullivan GJ, Carrasco M, Phatnani HP, Puddifoot CA, Story D, Fletcher J et al..  2012.  Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.. Proc Natl Acad Sci U S A. 109(15):5803-8.
Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA et al..  2012.  Guidelines for the use and interpretation of assays for monitoring autophagy.. Autophagy. 8(4):445-544.
Wray S, Self M, Lewis PA, Taanman J-W, Ryan NS, Mahoney CJ, Liang Y, Devine MJ, Sheerin U-M, Houlden H et al..  2012.  Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.. PLoS One. 7(8):e43099.
Sharma P, D Ando M, Daub A, Kaye JA, Finkbeiner S.  2012.  High-throughput screening in primary neurons.. Methods Enzymol. 506:331-60.
Gittis AH, Hang GB, LaDow ES, Shoenfeld LR, Atallah BV, Finkbeiner S, Kreitzer AC.  2011.  Rapid target-specific remodeling of fast-spiking inhibitory circuits after loss of dopamine.. Neuron. 71(5):858-68.
Korb E, Finkbeiner S.  2011.  Arc in synaptic plasticity: from gene to behavior.. Trends Neurosci. 34(11):591-8.
Klionsky DJ, Baehrecke EH, Brumell JH, Chu CT, Codogno P, Cuervo AMarie, Debnath J, Deretic V, Elazar Z, Eskelinen E-L et al..  2011.  A comprehensive glossary of autophagy-related molecules and processes (2nd edition).. Autophagy. 7(11):1273-94.
Zhang QCharles, Yeh T-lan, Leyva A, Frank LG, Miller J, Kim YE, Langen R, Finkbeiner S, Amzel ML, Ross CA et al..  2011.  A compact beta model of huntingtin toxicity.. J Biol Chem. 286(10):8188-96.
Finkbeiner S.  2011.  Huntington's Disease.. Cold Spring Harb Perspect Biol. 3(6)
Miller J, Arrasate M, Brooks E, Libeu CPeters, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S et al..  2011.  Identifying polyglutamine protein species in situ that best predict neurodegeneration.. Nat Chem Biol. 7(12):925-34.
Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S.  2010.  A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model.. Proc Natl Acad Sci U S A. 107(39):16982-7.
Kratter IH, Finkbeiner S.  2010.  PolyQ disease: too many Qs, too much function? Neuron. 67(6):897-9.
Peebles CL, Yoo J, Thwin MT, Palop JJ, Noebels JL, Finkbeiner S.  2010.  Arc regulates spine morphology and maintains network stability in vivo.. Proc Natl Acad Sci U S A. 107(42):18173-8.
Barmada S, Finkbeiner S.  2010.  Bringing SOD1 into the fold.. Nat Neurosci. 13(11):1303-4.
Finkbeiner S.  2010.  Bridging the Valley of Death of therapeutics for neurodegeneration.. Nat Med. 16(11):1227-32.
Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y et al..  2010.  Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.. J Biol Chem. 285(12):8808-23.
Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S.  2010.  Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis.. J Neurosci. 30(2):639-49.
Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, Paganetti P, Muchowski PJ, Wilson S, Bates GP.  2010.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.. Hum Mol Genet. 19(1):65-78.
Ramdzan YM, Nisbet RM, Miller J, Finkbeiner S, Hill AF, Hatters DM.  2010.  Conformation sensors that distinguish monomeric proteins from oligomers in live cells.. Chem Biol. 17(4):371-9.
Mitra S, Tsvetkov AS, Finkbeiner S.  2009.  Protein turnover and inclusion body formation.. Autophagy. 5(7):1037-8.
Daub A, Sharma P, Finkbeiner S.  2009.  High-content screening of primary neurons: ready for prime time.. Curr Opin Neurobiol. 19(5):537-43.
Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S, Merry DE.  2009.  Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy.. Hum Mol Genet. 18(11):1937-50.
Pintchovski SA, Peebles CL, Kim HJoo, Verdin E, Finkbeiner S.  2009.  The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons.. J Neurosci. 29(5):1525-37.
Mitra S, Tsvetkov AS, Finkbeiner S.  2009.  Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.. J Biol Chem. 284(7):4398-403.
Thompson LMichels, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JGire, Khashwji H et al..  2009.  IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome.. J Cell Biol. 187(7):1083-99.
Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LMichels, Wetzel R, X Yang W.  2009.  Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.. Neuron. 64(6):828-40.
Legleiter J, Lotz GP, Miller J, Ko J, Ng C, Williams GL, Finkbeiner S, Patterson PH, Muchowski PJ.  2009.  Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.. J Biol Chem. 284(32):21647-58.
Finkbeiner S, Mitra S.  2008.  The ubiquitin-proteasome pathway in Huntington's disease.. ScientificWorldJournal. 8:421-33.
Peebles CL, Finkbeiner S.  2007.  RNA decay back in play.. Nat Neurosci. 10(9):1083-4.
Rao VR, Finkbeiner S.  2007.  NMDA and AMPA receptors: old channels, new tricks.. Trends Neurosci. 30(6):284-91.
Finkbeiner S, Cuervo AMaria, Morimoto RI, Muchowski PJ.  2006.  Disease-modifying pathways in neurodegeneration.. J Neurosci. 26(41):10349-57.
M Beal F, Bossy-Wetzel E, Finkbeiner S, Fiskum G, Giasson B, Johnson C, Khachaturian ZS, Lee VM-Y, Nicholls D, Reddy H et al..  2006.  Common threads in neurodegenerative disorders of aging.. Alzheimers Dement. 2(4):322-6.
Rao VR, Pintchovski SA, Chin J, Peebles CL, Mitra S, Finkbeiner S.  2006.  AMPA receptors regulate transcription of the plasticity-related immediate-early gene Arc.. Nat Neurosci. 9(7):887-95.
Bradley J, Carter SR, Rao VR, Wang J, Finkbeiner S.  2006.  Splice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression.. J Neurosci. 26(4):1065-76.
Arrasate M, Finkbeiner S.  2005.  Automated microscope system for determining factors that predict neuronal fate.. Proc Natl Acad Sci U S A. 102(10):3840-5.
Peters-Libeu C, Newhouse Y, Krishnan P, Cheung K, Brooks E, Weisgraber K, Finkbeiner S.  2005.  Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches.. Acta Crystallogr Sect F Struct Biol Cryst Commun. 61(Pt 12):1065-8.
Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S.  2004.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.. Nature. 431(7010):805-10.
Brooks E, Arrasate M, Cheung K, Finkbeiner S.  2004.  Using antibodies to analyze polyglutamine stretches.. Methods Mol Biol. 277:103-28.
Rao VR, Finkbeiner S.  2003.  Secrets of a secretase: N-cadherin proteolysis regulates CBP function.. Cell. 114(5):533-5.
Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F.  2002.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.. Dev Cell. 2(6):831-7.
Bradley J, Finkbeiner S.  2002.  An evaluation of specificity in activity-dependent gene expression in neurons.. Prog Neurobiol. 67(6):469-77.
Finkbeiner S.  2000.  Calcium regulation of the brain-derived neurotrophic factor gene.. Cell Mol Life Sci. 57(3):394-401.
Finkbeiner S.  2000.  CREB couples neurotrophin signals to survival messages.. Neuron. 25(1):11-4.
Finkbeiner S, Dalva MB.  1998.  To fear or not to fear: what was the question? A potential role for Ras-GRF in memory. Bioessays. 20(9):691-5.
Finkbeiner S, Greenberg ME.  1998.  Ca2+ channel-regulated neuronal gene expression.. J Neurobiol. 37(1):171-89.
Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME.  1998.  Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism.. Neuron. 20(4):709-26.
Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME.  1997.  CREB: a major mediator of neuronal neurotrophin responses.. Neuron. 19(5):1031-47.
Finkbeiner S, Greenberg ME.  1997.  Spatial features of calcium-regulated gene expression.. Bioessays. 19(8):657-60.
Finkbeiner S.  1993.  Glial calcium.. Glia. 9(2):83-104.
Finkbeiner S.  1992.  Calcium waves in astrocytes-filling in the gaps.. Neuron. 8(6):1101-8.
van den Pol AN, Finkbeiner S, Cornell-Bell AH.  1992.  Calcium excitability and oscillations in suprachiasmatic nucleus neurons and glia in vitro.. J Neurosci. 12(7):2648-64.
Renzi R, Finkbeiner S.  1991.  Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect.. Am J Emerg Med. 9(6):551-2.
Cornell-Bell AH, Finkbeiner S.  1991.  Ca2+ waves in astrocytes.. Cell Calcium. 12(2-3):185-204.
Goldman RS, Finkbeiner S, Smith SJ.  1991.  Endothelin induces a sustained rise in intracellular calcium in hippocampal astrocytes.. Neurosci Lett. 123(1):4-8.
Cornell-Bell AH, Finkbeiner S, Cooper MS, Smith SJ.  1990.  Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling.. Science. 247(4941):470-3.
Keana JF, McBurney RN, Scherz MW, Fischer JB, Hamilton PN, Smith SM, Server AC, Finkbeiner S, Stevens CF, Jahr C.  1989.  Synthesis and characterization of a series of diarylguanidines that are noncompetitive N-methyl-D-aspartate receptor antagonists with neuroprotective properties.. Proc Natl Acad Sci U S A. 86(14):5631-5.
Goldman RS, Finkbeiner S.  1988.  Therapeutic use of magnesium sulfate in selected cases of cerebral ischemia and seizure.. N Engl J Med. 319(18):1224-5.
Finkbeiner S, Stevens CF.  1988.  Applications of quantitative measurements for assessing glutamate neurotoxicity.. Proc Natl Acad Sci U S A. 85(11):4071-4.